World Alzheimer’s Day 2026: Is Clinical Research Ready for the Next Era of Alzheimer’s Trials?

Alzheimer’s research is entering a new phase. Advances in biomarkers are making it possible to identify biological signs of the disease earlier, clinical trials are increasingly reaching people before significant cognitive decline, and the drug pipeline is expanding beyond its traditional focus on amyloid.

These advances are changing not only how Alzheimer’s is understood and treated, but also how clinical trials need to be run. As studies move earlier in the disease course and target more precisely defined patient populations, sponsors face new questions around recruitment, screening and trial design.

On World Alzheimer’s Day 2026, we look at five developments that are reshaping Alzheimer’s clinical research and what they mean for sponsors developing the next generation of treatments.

Alzheimer’s Trials Are Moving Before Symptoms

Alzheimer’s drug development is moving earlier in the disease course. Of the 54 Phase 3 trials in the 2026 pipeline, several are already targeting preclinical, prodromal or mild cognitive impairment populations rather than established dementia.

The AHEAD Study illustrates this shift. It is testing lecanemab in cognitively unimpaired adults who already show amyloid changes in the brain. The goal is increasingly to intervene before memory loss becomes apparent, much like managing high cholesterol before it leads to a heart attack.

For sponsors, this creates a new recruitment challenge. Traditional Alzheimer’s trials can recruit through memory clinics, where patients arrive after cognitive problems emerge. Prevention trials need to find people who may feel completely healthy, identify biological signs of disease and determine who meets the protocol criteria. As Alzheimer’s trials move earlier, recruitment and biomarker-based prescreening will need to move earlier with them.

Blood Biomarkers Could Change How Alzheimer’s Trials Recruit

Blood tests are becoming more than a diagnostic tool. They could also change how Alzheimer’s trials find and screen participants.

At AAIC 2026, a real-world study of more than 1,300 patients showed that access to a blood biomarker test increased diagnostic accuracy among primary care physicians from 65% to 93%. Another study, published in JAMA, found that cognitively healthy adults with very high levels of p-tau217 had an estimated 78% risk of developing cognitive impairment within 10 years. Together, these findings point to a future in which potential trial participants can be identified much earlier and outside specialist memory centers.

That shift is already reaching clinical trials. In GSK’s Phase 2 PROGRESS-AD study, blood biomarkers were used to identify participants more likely to be amyloid-positive before confirmatory PET or cerebrospinal fluid testing. The approach reduced the screen failure rate for amyloid confirmation to 9.9% and limited unnecessary PET scans and lumbar punctures.

For sponsors, the recruitment funnel could become much more targeted: screen broadly with a blood test, identify the most relevant candidates, and reserve more complex testing for those most likely to qualify.

More Trials Mean More Competition for Participants

The Alzheimer’s pipeline is growing, and so is the demand for trial participants. According to the 2026 pipeline report, 158 drugs are being studied across 192 active trials, requiring an estimated 54,728 participants. More than 38,000 of them are needed for Phase 3 trials alone.

For sponsors, those numbers highlight a growing recruitment challenge. Many studies are looking for increasingly specific populations, defined not only by symptoms but also by disease stage and biomarkers. At the same time, multiple programs may be recruiting from the same limited pool of eligible participants.

As the pipeline expands, recruitment capacity becomes an increasingly important part of development strategy. It is not enough to design the right trial, sponsors also need to know where the right participants can realistically be found.

Beyond Amyloid Means More Complex Trials

Alzheimer’s research is no longer dominated by amyloid alone. Over the past decade, amyloid-targeted drugs have fallen from 33% to around 20% of the pipeline, while tau and inflammation/immune targets have each grown from about 6% to roughly 20%.

This broader pipeline also brings new development challenges. Biogen’s Phase 2 CELIA trial of the tau-targeting drug diranersen missed its primary endpoint, yet showed strong reductions in tau biomarkers and encouraging signals on several cognitive measures. Biogen is now planning registrational development.

Semaglutide shows the other side of that uncertainty. Novo Nordisk’s two Phase 3 trials enrolled 3,808 participants, but failed to slow clinical progression despite promising earlier evidence.

For sponsors, a more diverse pipeline means more biomarkers, endpoints and biological pathways and more complex decisions about which signals are strong enough to move a program forward.

Alzheimer’s Trials Are Testing More Than Drugs

Alzheimer’s prevention research is also moving toward more complex study designs. The newly announced PROTECT-Cog study will test whether combining a multidomain lifestyle intervention with a metabolism-targeting drug can further reduce the risk of cognitive decline in at-risk older adults. Participants will be followed for three years, combining drug treatment with structured lifestyle programs and regular cognitive and health assessments.

For sponsors, studies like this introduce a different kind of complexity. Success depends not only on delivering the investigational treatment, but also on maintaining participant engagement and adherence across multiple interventions over several years.

Rethinking Alzheimer’s Trial Strategy

Alzheimer’s trials are becoming more precise, but also more demanding to execute. Finding the right participants increasingly depends on access to referral networks, biomarker testing and diagnostic infrastructure, not simply on a site’s previous enrollment numbers.

For sponsors, this also makes geographic strategy increasingly important. Phase 3 Alzheimer’s development is already highly international: 63% of Phase 3 trials include sites both in North America and other regions. As studies target earlier and more biologically defined populations, expanding recruitment across countries can provide access to broader patient pools and reduce reliance on highly competitive research centers.

For sponsors, the ability to identify the right countries, sites and participants may become as important as the science behind the treatment itself.

At Cromos Pharma, we support sponsors in translating complex development strategies into trials that work in the real world, from feasibility and country and site selection to patient recruitment and study delivery. As Alzheimer’s research evolves, successful development will increasingly depend on building the right operational strategy around the science.

If you are planning an Alzheimer’s or other CNS clinical trial, contact our team at inquiry@cromospharma.com to discuss how we can support your development program.